Transaction details
Thomas E. Chorman, a director of Standex International Corp (NYSE:SXI), completed a sale of 513 shares of company common stock on February 27, 2026, according to a recent SEC filing. The shares were sold at $260.00 apiece, yielding total proceeds of $133,380. After the sale, Chorman directly holds 12,666 shares of Standex International.
Share-price context
The sale took place as Standex's stock trades near a 52-week high of $270.87. The share price has risen substantially from its 52-week low of $128.84, an increase in excess of 100% from that low, and the company reports a one-year return of nearly 42%.
Valuation and market commentary
Analysis from InvestingPro indicates the stock currently appears overvalued relative to its Fair Value. InvestingPro Tips also call out a significant price uptick over the past six months and note Standex has increased its dividend for 15 consecutive years. The platform references 13 additional ProTips and a more detailed Pro Research Report available to subscribers.
Recent financial performance
In its fiscal 2026 second quarter, Standex International reported adjusted earnings per share of $2.08, topping the forecasted $2.00. Revenue for the quarter reached $221.3 million, slightly ahead of the $219.22 million consensus. No recent analyst upgrades or downgrades were reported in conjunction with these results.
Implications
The insider sale is a discrete, disclosed transaction that occurred while the stock was trading near its year-high range. The company's quarterly results modestly exceeded expectations on both EPS and revenue, and InvestingPro's valuation assessment suggests a divergence between market price and the platform's Fair Value estimate. The combination of stronger-than-expected quarterly results, a long history of dividend increases noted by InvestingPro, and a current valuation flagged as rich frames the immediate public signals available to investors.
What remains limited
The public filings and the InvestingPro summary provide concrete transaction details and snapshot analysis, but they do not include any recent analyst rating changes tied to the quarter, nor do they supply further management commentary or forward guidance in the materials cited. Readers should note those limitations when interpreting the significance of the director's sale and the company's reported quarter.